Furthermore, the melanoma antigen gp100 has emerged as a pivotal factor in directing in vivo tumor rejection responses via immune reactions facilitated by tumor-infiltrating lymphocytes (TILs) in individuals with melanoma 34. The gene discussed is PMEL; the disease is melanoma.